Get the Stockscreener App
7.17
3.31%
0.23
Verastem Inc stock is traded at $7.17, with a volume of 2.62M.
It is up +3.31% in the last 24 hours and up +35.80% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$6.94
Open:
$7.15
24h Volume:
2.62M
Relative Volume:
2.74
Market Cap:
$382.57M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.7445
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
-3.50%
1M Performance:
+35.80%
6M Performance:
+81.52%
1Y Performance:
-39.85%
1-Day Range:
$6.96
$7.56
1-Week Range:
$6.35
$8.00
52-Week Range:
$2.10
$13.52
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
7.17 | 382.57M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased - MSN
Verastem (VSTM) Sees Price Target Increase and FDA Approval Boos - GuruFocus
Verastem (VSTM) Sees Increased Price Target Following FDA Approval | VSTM Stock News - GuruFocus
High-graded low-grade ovarian duo wins for Verastem at FDA - BioWorld MedTech
B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating - marketscreener.com
Verastem (VSTM) Stock Update: Analyst Raises Price Target to $14 | VSTM Stock News - GuruFocus
RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Verastem (VSTM) Price Target Increased by RBC Capital Analyst | VSTM Stock News - GuruFocus
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - BioSpace
Verastem stock price target raised to $19 by Jefferies - Investing.com Canada
Verastem Gains FDA Approval for New Cancer Treatment - TipRanks
Health Care Stocks See Mixed Results In Market Movements - Finimize
Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer - insights.citeline.com
Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer - MedCity News
FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC - Pharmacy Times
US FDA approves Verastem's ovarian cancer therapy - Reuters
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer - Yahoo Finance
US FDA approves Verastem’s cancer therapy - WHTC
Verastem (VSTM) Gains as Analyst Increases Price Target Following FDA Approval | VSTM Stock News - GuruFocus
Verastem Oncology Cancer Drug Combination Gets FDA Approval - marketscreener.com
FDA grants Verastem first approval for rare ovarian cancer treatment - Endpoints News
Verastem Says AVMAPKI FAKZYNJA Co-Pack Expected To Be Available For Adult Patients In U.S. In One Week - marketscreener.com
FDA Greenlights Verastem's (VSTM) New Cancer Treatment - GuruFocus
Verastem's Avmapki Fakzynja receives FDA accelerated approval for ovarian cancer - Seeking Alpha
U.S. FDA approves Verastem's cancer therapy - marketscreener.com
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo | VSTM Stock News - GuruFocus
Trading (VSTM) With Integrated Risk Controls - news.stocktradersdaily.com
Invesco Ltd. Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
B. Riley Issues Pessimistic Outlook for Verastem Earnings - Defense World
Verastem (VSTM) Schedules Conference Call with Key Executives | - GuruFocus
Verastem Oncology to Present at Upcoming Investor Conferences | - GuruFocus
Ovarian Cancer Market: Epidemiology, Therapies, Companies, - openPR.com
Verastem Oncology to Present at Upcoming Investor Conferences - Bluefield Daily Telegraph
Verastem, Inc. (NASDAQ:VSTM) Stock Holdings Lowered by XTX Topco Ltd - The AM Reporter
Verastem (VSTM) to Release Earnings on Thursday - Defense World
B. Riley Has Positive Forecast for Verastem FY2029 Earnings - Defense World
BlackRock, Inc. Expands Stake in Verastem Inc. with Recent Acqui - GuruFocus
Does Verastem Inc (VSTM) offer a good opportunity for investors? - Sete News
Ratio Review: Analyzing Verastem Inc (VSTM)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Recent Insider Activity Suggests Potential Gains for Verastem Inc (VSTM) - knoxdaily.com
It would be worthwhile to take a closer look at Verastem Inc (VSTM) - uspostnews.com
Verastem Inc: Analyzing VSTM Stock Trends - investchronicle.com
Analyze Verastem Inc (NASDAQ: VSTM) Before Investing. - Stocksregister
Verastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLC - Defense World
Verastem Oncology rises on $75M private placement - MSN
Verastem Oncology secures $75 million in private placement By Investing.com - Investing.com India
Verastem Inc [VSTM] Shares Rise 5.34 % on Thursday - knoxdaily.com
Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical hold - Endpoints News
Verastem Oncology rises after $75 million private placement - TradingView
Verastem Shares Rise After Agreement to Sell Securities Worth Roughly $75 Million - marketscreener.com
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):